what’s new in pca... steven joniau university hospitals leuven, belgium eau guidelines 2010 update
TRANSCRIPT
What’s new in PCA...
Steven Joniau
University Hospitals Leuven, Belgium
EAU Guidelines 2010 update
PCA Guideline Panel
Axel Heidenreich (Chairman) Urology Germany
Joacqim Bellmunt Medical Oncology Spain
Michel Bolla Radiation Oncology France
Steven Joniau Urology Belgium
Theodor van der Kwast Pathology Canada
Malcom Mason Radiation Oncology UK
Veseled Matveev Urology Russia
Nicolas Mottet Urology France
Hans Peter Schmid UrologySwitzerland
Thomas Wiegel Radiation Oncology Germany
Francesco Zattoni Urology Italy
Screening
Schröder et al.New Engl J Med 2009
Andriole et al.New Engl J Med 2009
Risk reduction 27%Numbers needed to screen 1410Numbers needed to treat 48 No significant difference
Screening
Risk adapted early detection
Active Surveillance
• Active Surveillance• close follow-up examinations under strict rules of
guidelines• Purpose: Identification & treatment of significant
PCA, curative intent
• Watchful Waiting• withhold treatment until development of disease-
specific symptoms• Purpose: symptom-based therapy, palliative intent
Active Surveillance: why?
Because it• avoids overtreatment with insignificant or slowly
proliferating prostate cancer
• avoids unnecessary impairment of quality of life
• Is a viable alternative for elderly and co morbid patients who harbour a higher mortality risk from non-cancer specific causes
Active Surveillance
Inclusion Criteria• PSA ≤ 10 ng/ml• Biopsy Gleason Score ≤ 6• ≤ 2 positive biopsies• ≤ 50% cancer per biopsy• cT1c – cT2a
Intervention required• Biopsy Gleason Score > 6• PSA-DT < 3 years• cancer volume • patient’s preference
Adjuvant Radiation Therapy
• Bolla et al.• EORTC 22911: 60 Gy vs Wait-and-See • pT3a, pT3b, pTxpR1 independent on postop. PSA
• Wiegel et al.• ARO 96-02: 60 Gy vs Wait-and-See• pT3a-bpN0, PSA negative !
• Swanson et al.• SWOG 8794: 60-64 Gy vs Wait-and-See• pT3a, pT3b, pTxpR1 independent on postop. PSA
Adjuvant Radiation Therapy
Radiation W & S
R0 76.2% 67.4%
R1 77.6% 48.5%*
R0 + Rad R1 + Rad
HR 0.87 0.38
Benefit 88/1000 291/1000
EORTC 22911
Adjuvant Radiation Therapy
72%
54%
ARO/AUO – German Study
Adjuvant Radiation Therapy
ARO/AUO – German Study
5 year F-up: 25% benefit for progression-free survival
pT3aR1
SWOG 8794
Survellance Survellance adj. Radiationadj. Radiation
Adjuvant Radiation Therapy
SWOG 8794
Wait-and-See Radiation
PSA ≤ 0.2 0.21 – 1.0 ≤ 0.2 0.21 – 1.0
PSA 59% 23% 77% 34%
Local relapse
20% 25% 7% 9%
Metastases 12% 16% 4% 12%
Adjuvant Radiation Therapy
Adjuvant Radiation Therapy
Intermittend Androgen Deprivation
Cyclic therapy
• On-treatment period
• Off-treatment period
IHT aims to
• Minimise adverse events / improve quality of life (QoL)
• Delay progression to hormone resistant Pca
• Reduce costs of care
Intermittend Androgen Deprivation
Trial Population # patients randomised
NCIC/PR7 PSA relapse after RT ±300
EC 507 PSA relapse after RP 201
ICELAND PSA relapse/locally advanced ±700
SEUG Advanced PCa 626
Japan Locally advanced 188
AP 17/95 Advanced PCa and M+ 335
SWOG 9346 M+ PCa (PSA > 5 ng/mL) 1,345
EC 210 M+ PCa (PSA > 20 ng/mL) 194
Europe Advanced PCa (90% T3) 914
Intermittend Androgen Deprivation
Calais da Silva FEC et al. ; Eur Urol 2009
Intermittend Androgen Deprivation
EC507: IHT does not affect progression-free survival
Tunn U. BJU Int 2007;99(Suppl 1)
Intermittend Androgen Deprivation
Follow-up: local
Follow-up: ADT
Follow-up: ADT
CAVE: Diabetes mellitusMetabolic SyndromCholesterine, TriglycerideCholesterine/HDL - Ratio
Follow-up: cancer specific: PSA, Tendocrinologicmetaboliccardiovascular